Treatment response was superior to that in the SGST group: the reduction in IGF1 was in the range 20%‐50% in 2 patients (SLT and DGST), in 6 patients (3 DGST and 3 SLT) the reduction was by more than 50%, and in 6 patients the IGF1 level was fully normalized (5 SLT and 1 plurihormonal tumour). Here, IGF1 is linked to neoplasm.